Compare PDLB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | ARVN |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.1M | 516.2M |
| IPO Year | 2021 | 2018 |
| Metric | PDLB | ARVN |
|---|---|---|
| Price | $20.72 | $9.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $15.05 |
| AVG Volume (30 Days) | 63.4K | ★ 836.3K |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 58.84 |
| EPS | 0.71 | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.13 | ★ $5.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.91 | $6.96 |
| 52 Week High | $20.79 | $14.22 |
| Indicator | PDLB | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 60.13 |
| Support Level | $19.49 | $7.90 |
| Resistance Level | N/A | $9.65 |
| Average True Range (ATR) | 0.46 | 0.39 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 87.16 | 60.40 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.